| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Earnings Call zu Orexo AB: Aktie bricht nach Umsatzverfehlung im dritten Quartal 2025 ein | 1 | Investing.com Deutsch | ||
| Do | Orexo Q3 2025 slides: Revenue miss overshadows AmorphOX pipeline progress | 1 | Investing.com | ||
| Do | Orexo AB Q3 Loss Narrows | 1 | RTTNews | ||
| Do | Orexo AB: Orexo Q3 2025 Interim Report | 66 | GlobeNewswire (Europe) | Unlocking the potential of the AmorphOX® technologyQ3 2025 highlights› Total net revenues of SEK 118.7 m (136.5)› EBITDA of SEK -9.8 m (-0.7), including a negative impact from costs associated with... ► Artikel lesen | |
| 01.10. | Orexo AB: Orexo strengthens innovation and research with move to new premises | 53 | GlobeNewswire (Europe) | Uppsala, Sweden, October 1, 2025 - Orexo AB (Publ.), (STO:ORX) (OTCQX:ORXOY) is taking the next step in its development journey by relocating to new, modern premises in Uppsala Science Park. The move... ► Artikel lesen | |
| 30.09. | Orexo US Awarded $8M in Funding by BARDA | 1 | Contract Pharma | ||
| OREXO Aktie jetzt für 0€ handeln | |||||
| 29.09. | Orexo AB: Orexo US Awarded USD 8 Million by BARDA for OX390 Development Partnership | 284 | GlobeNewswire (Europe) | Uppsala, Sweden - September 29, 2025 - Orexo AB (Publ.), (STO:ORX) (OTCQX:ORXOY), today announced its wholly owned US subsidiary, Orexo US, Inc., has been awarded USD 8 million in funding by the Biomedical... ► Artikel lesen | |
| 05.09. | Orexo's AmorphOX technology may pave the way for intranasal GLP-1 medication | 860 | PR Newswire | A preclinical pharmacokinetic in-vivo study has been conducted in which the AmorphOX® technology was used to develop three powder-based intranasal formulations with semaglutide, which were... ► Artikel lesen | |
| 29.08. | Seminar: IP That Matters - Behind Orexo's Milestone Patent Win at the US Court | 343 | PR Newswire | UPPSALA, Sweden, Aug. 29, 2025 /PRNewswire/ -- Orexo (publ.), (STO: ORX) (OTCQX: ORXOY) in collaboration with its advisory international law firms Potter Clarkson LLP and Steptoe LLP, will... ► Artikel lesen | |
| 16.07. | Orexo Q2 2025 slides: Maintains full-year outlook despite FX headwinds | 1 | Investing.com | ||
| 16.07. | Orexo hält trotz Währungsgegenwind an Jahresprognose für 2025 fest | 1 | Investing.com Deutsch | ||
| 16.07. | Orexo AB: Orexo Q2 2025 Interim Report | 211 | GlobeNewswire (Europe) | 2025 outlook remains amid currency headwinds and non-recurring effectQ2 2025 highlights› Total net revenues of SEK 118.2 m (154.0), including a non-recurring rebate payment of SEK 8.9 m› EBITDA of SEK... ► Artikel lesen | |
| 02.06. | Orexo to present clinical data for OX640 at the EAACI Congress | 269 | PR Newswire | OX640 is a nasal rescue medication with powder-based epinephrine for the treatment of severe allergic reactions (including anaphylaxis) and is based on the proprietary AmorphOX® technologyEAACI... ► Artikel lesen | |
| 06.05. | Orexo Q1 2025 slides: stable revenue growth amid pipeline advancements | 1 | Investing.com | ||
| 06.05. | Orexo AB: Orexo Q1 2025 Interim Report | 235 | GlobeNewswire (Europe) | Q1 2025 highlights› Total net revenues of SEK 146.2 m (139.3)› EBITDA of SEK 5.9 m (15.9)› Net earnings of SEK -15.9 m (-8.9)› US Commercial segment net revenues of SEK 133.0 m (129.3), in local currency... ► Artikel lesen | |
| 10.04. | Orexo announces positive data for powder-based intranasal vaccine formulated with the AmorphOX technology | 412 | PR Newswire | The study was conducted in partnership with Abera Bioscience, a platform and vaccine developer with over 30 years of research in the medical, molecular and microbiological fields.Both formulations... ► Artikel lesen | |
| 06.02. | Orexo AB: Orexo Interim Report Q4 2024, incl. Full Year Report | 195 | GlobeNewswire (Europe) | Q4 2024 highlights› Total net revenues of SEK 160.3 m (166.0)› EBITDA of SEK 28.9 m (12.4)› Impairment of intangible assets Deprexis® of SEK 71.1 m (0) and Vorvida® of SEK 28.1 m (0)› Net earnings of... ► Artikel lesen | |
| 10.01. | Orexo announces positive topline data from clinical study of OX640 in subjects with and without allergic rhinitis | 499 | PR Newswire | OX640 is a nasal rescue medication with powder-based epinephrine for the treatment of allergic reactions (incl. anaphylaxis) and is based on the proprietary AmorphOX® technology.The clinical... ► Artikel lesen | |
| 17.12.24 | Orexo enters into collaboration with Abera to develop nasal powder vaccines based on the AmorphOX technology | 522 | PR Newswire | The collaboration is in line with Orexo's strategy to broaden the use of its powder-based drug delivery technology AmorphOX®.Abera is a developer of mucosal vaccines and has several preclinical... ► Artikel lesen | |
| 02.12.24 | Orexo AB: Orexo and GAIA agree to terminate the partnership for Deprexis | 450 | GlobeNewswire (Europe) | Uppsala, Sweden - December 2, 2024 - Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY), today announces that Orexo AB and GAIA AG have decided to terminate the partnership agreement, covering the rights for... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| AURORA CANNABIS | 4,340 | -0,80 % | Aurora Cannabis Inc (3): Aurora Cannabis to issue Q2 fiscal 2026 results Nov. 5 | ||
| ABBVIE | 195,40 | -0,10 % | AbbVie erzielt positive Studienergebnisse mit RINVOQ bei rheumatoider Arthritis | Der US-Pharmakonzern AbbVie hat in einer späten klinischen Studie positive Ergebnisse für seinen Wirkstoff Upadacitinib (Handelsname RINVOQ) erzielt. In der Phase-3b/4-Studie SELECT-SWITCH wurde das... ► Artikel lesen | |
| TILRAY BRANDS | 1,247 | -0,91 % | Tilray Brands-Aktie sorgt für Gesprächsstoff - was Anleger jetzt genau verfolgen müssen! | ||
| BRISTOL-MYERS SQUIBB | 37,420 | +0,40 % | Evotec erhält 25 Millionen US-Dollar von Bristol-Myers Squibb | Evotec SE hat im Rahmen der Neurologie-Partnerschaft mit Bristol-Myers Squibb eine Zahlung von 25 Millionen US-Dollar erhalten. Die Summe steht im Zusammenhang mit Fortschritten in der gemeinsamen präklinischen... ► Artikel lesen | |
| TEVA | 16,800 | -0,30 % | Formycon und Teva starten Vertrieb von FYB201-Fertigspritze | Die Formycon AG hat gemeinsam mit Bioeq und Teva Pharmaceutical Industries die Markteinführung von FYB201/Ranivisio, dem ersten in Europa zugelassenen Ranibizumab-Biosimilar in einer Fertigspritze,... ► Artikel lesen | |
| BAUSCH HEALTH | 5,333 | +0,09 % | Bausch Health Companies Inc.: Bausch Health Announces Results of Special Meeting of Shareholders | LAVAL, QC / ACCESS Newswire / October 9, 2025 / Bausch Health Companies Inc. (the "Company") (NYSE:BHC)(TSX:BHC) today announced the results of the special meeting of shareholders held on October 7... ► Artikel lesen | |
| BIONANO GENOMICS | 1,910 | -1,29 % | Bionano Genomics, Inc. Announces Closing of $10 Million Public Offering | SAN DIEGO, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ: BNGO) ("Bionano" or the "Company") today announced the closing of its previously announced public offering of an aggregate... ► Artikel lesen | |
| OPKO HEALTH | 1,282 | +2,64 % | Here's Why You Should Add OPKO Health Stock to Your Portfolio | ||
| JAGUAR HEALTH | 2,035 | +0,25 % | Jaguar Health, Inc.: Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635 | SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / October 24, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that, effective October 20, 2025, the Company granted 600... ► Artikel lesen | |
| MALLINCKRODT | - | - | Mallinckrodt plc - 8-K, Current Report | ||
| AVALO THERAPEUTICS | 15,060 | -2,59 % | Avalo Therapeutics: Avalo Reports Second Quarter 2025 Financial Results and Recent Business Updates | Topline data from Phase 2 LOTUS trial of AVTX-009 for the treatment of hidradenitis suppurativa expected mid-2026Rita Jain, M.D. appointed to Board of DirectorsCash and short-term investments of approximately... ► Artikel lesen | |
| BAYER | 27,610 | -0,59 % | KI-Hausse und DAX Dauer-Feuerwerk! Weitere 100 % mit NetraMark, Bayer und Novo Nordisk | Pfiffige Anleger haben schon Wind davon bekommen! Künstliche Intelligenz revolutioniert die Arzneimittelforschung und drückt die Entwicklungskosten radikal. Algorithmen entdecken dabei molekulare Muster... ► Artikel lesen | |
| MERCK KGAA | 114,40 | -0,56 % | Merck-Aktie: Drei Sparten - ein Wachstumsplan | Der Darmstädter DAX-Konzern hat einen großen Umbau hinter sich. In den Zahlen spiegelt sich dieser noch nicht wider. Etwas Geduld könnte sich auszahlen, denn das Kurspotenzial ist hoch. Er hätte für... ► Artikel lesen | |
| GSK | 18,845 | +1,48 % | Alzheimer-Rückschlag: GSK-Partner Alector crasht - gelingt Novo Nordisk die Überraschung des ... | Ein weiterer Studienrückschlag belastet die Demenzforschung. Die US-Biotech-Gesellschaft Alector und der britische Pharma-Partner GSK stellen die Entwicklung des Wirkstoffes Latozinemab ein. Trotz wichtiger... ► Artikel lesen | |
| ASTRAZENECA | 143,85 | +0,31 % | Führende Fortune-500-Unternehmen wie AstraZeneca, Johnson & Johnson, General Mills und Kraft Heinz berichten im Rahmen einer OMP-Konferenz über KI-Kompetenzen zur Stärkung der Lieferkette | Branchenriesen wie AstraZeneca, Johnson & Johnson, General Mills und Kraft Heinz präsentieren in Miami Fallstudien aus
der Praxis
MIAMI, FL / ACCESS Newswire /
22. Oktober... ► Artikel lesen |